Concert Pharmaceuticals to Present at Upcoming Investor Conferences

LEXINGTON, Mass.--(BUSINESS WIRE)-- Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that it will participate at the following upcoming investor conferences:

• The UBS Global Healthcare Conference on May 21, 2019 at 10:00 a.m. ET in New York, NY;
• The Jefferies 2019 Global Healthcare Conference on June 5, 2019 at 10:30 a.m. ET in New York, NY; and
• The JMP Securities Life Sciences Conference on June 19, 2019 at 9:00 a.m. ET in New York, NY.

Live webcasts of the presentations may be accessed in the Investors section of the Company’s website at www.concertpharma.com. Please log on to the Concert website approximately 15 minutes prior to the scheduled webcast to ensure adequate time for any software downloads that may be required. A replay of the conference webcasts will be available on Concert’s website for two weeks following the presentations.

About Concert

Concert Pharmaceuticals is a clinical stage biopharmaceutical company focused on applying its DCE Platform® (deuterated chemical entity platform) to create novel medicines designed to treat serious diseases and address unmet patient needs. The Company’s approach starts with previously studied compounds, including approved drugs, in which deuterium substitution has the potential to enhance clinical safety, tolerability or efficacy. Concert’s pipeline of innovative medicines targets autoimmune diseases and central nervous systems (CNS) disorders. For more information please visit www.concertpharma.com or follow us on Twitter at @ConcertPharma or on LinkedIn.

Concert Pharmaceuticals Inc., the CoNCERT Pharmaceuticals Inc. logo and DCE Platform are registered trademarks of Concert Pharmaceuticals, Inc.

View source version on businesswire.com: https://www.businesswire.com/news/home/20190514005115/en/

Justine Koenigsberg
(781) 674-5284
[email protected]

Source: Concert Pharmaceuticals, Inc.

You May Also Be Interested In

• Greenville Technical College Opens Center for Welding & Automation Excellence
• IMPACT Silver Reports Q2 2026 Results: Revenue Increased by 124%, Gross Profit up 756% on Silver Leverage, Higher Grades
• Grandmaster Tan Zhongyi Claims Second Cairns Cup Crown